Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Similar articles for PubMed (Select 22046096)

1.

Esophageal mucosal lesion with low-dose aspirin and prasugrel mimics malignancy: a case report.

Ma GF, Gao H, Chen SY.

World J Gastroenterol. 2011 Sep 21;17(35):4048-51. doi: 10.3748/wjg.v17.i35.4048.

2.

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.

Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.

Circulation. 2013 Aug 20;128(8):823-33. doi: 10.1161/CIRCULATIONAHA.113.002303. Epub 2013 Jul 12.

3.

Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel.

Serebruany VL, Dinicolantonio JJ, Can MM, Goto S.

Cardiology. 2013;124(2):85-90. doi: 10.1159/000346382. Epub 2013 Jan 30.

PMID:
23369842
4.

Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.

Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A.

J Am Coll Cardiol. 2013 May 21;61(20):2060-6. doi: 10.1016/j.jacc.2013.02.036. Epub 2013 Mar 21.

5.

Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.

Serebruany VL, Dinicolantonio JJ, Can MM, Pershukov IV, Kuliczkowski W.

Cardiology. 2013;126(1):35-40. doi: 10.1159/000350961. Epub 2013 Jul 12.

PMID:
23860246
6.

Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.

[No authors listed]

Prescrire Int. 2009 Oct;18(103):193-5.

PMID:
19877380
7.

Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.

Clemmensen P, Dridi NP, Holmvang L.

Cardiovasc Drugs Ther. 2013 Jun;27(3):239-45. doi: 10.1007/s10557-013-6444-2. Review.

PMID:
23380983
8.

Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38).

Hochholzer W, Wiviott SD, Antman EM, Contant CF, Guo J, Giugliano RP, Dalby AJ, Montalescot G, Braunwald E.

Circulation. 2011 Jun 14;123(23):2681-9. doi: 10.1161/CIRCULATIONAHA.110.002683. Epub 2011 May 23.

9.

Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel.

Parodi G, Bellandi B, Venditti F, Carrabba N, Valenti R, Migliorini A, Grassellini S, Ramazzotti E, Antoniucci D.

Am J Cardiol. 2012 Jan 15;109(2):214-8. doi: 10.1016/j.amjcard.2011.08.034. Epub 2011 Oct 12.

PMID:
21996146
10.

Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity.

Gaglia MA Jr, Torguson R, Pokharel S, Pakala R, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R.

Cardiovasc Revasc Med. 2013 Mar-Apr;14(2):76-80. doi: 10.1016/j.carrev.2012.12.005. Epub 2013 Jan 31.

PMID:
23375617
11.

Prasugrel during primary percutaneous coronary intervention: evidence from clinical data.

Biondi-Zoccai G, Abbate A, D'Ascenzo F, Lotrionte M, Modena MG.

Curr Vasc Pharmacol. 2012 Jul;10(4):454-7.

PMID:
22339255
13.

Does dual antiplatelet therapy affect blood loss and transfusion requirements in robotic-assisted coronary artery surgery?

Hemli JM, Darla LS, Panetta CR, Jennings J, Subramanian VA, Patel NC.

Innovations (Phila). 2012 Nov-Dec;7(6):399-402. doi: 10.1097/IMI.0b013e3182851779.

PMID:
23422801
14.

Antiplatelet options for secondary prevention in acute coronary syndromes.

Silvain J, Cayla G, O'Connor SA, Collet JP, Montalescot G.

Expert Rev Cardiovasc Ther. 2011 Nov;9(11):1403-15. doi: 10.1586/erc.11.139. Review.

PMID:
22059790
15.

Desensitization to prasugrel: cardiology's increased need for allergy consultation.

Mutnick JL.

Ann Allergy Asthma Immunol. 2012 Feb;108(2):124-5. doi: 10.1016/j.anai.2011.11.005. Epub 2011 Dec 3. No abstract available.

PMID:
22289733
16.

Dual antiplatelet agent-induced spontaneous liver hematoma.

Darwish OS, Iqbal E.

Ann Pharmacother. 2012 Nov;46(11):e33. doi: 10.1345/aph.1R183. Epub 2012 Oct 16.

PMID:
23073305
17.

Acute coronary syndromes: identifying the appropriate patient for prasugrel.

Stephens JC, Askari AT.

Postgrad Med. 2012 Mar;124(2):16-28. doi: 10.3810/pgm.2012.03.2533. Review.

PMID:
22437212
18.

Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.

Price MJ, Walder JS, Baker BA, Heiselman DE, Jakubowski JA, Logan DK, Winters KJ, Li W, Angiolillo DJ.

J Am Coll Cardiol. 2012 Jun 19;59(25):2338-43. doi: 10.1016/j.jacc.2012.02.042.

19.

Prasugrel-induced rash.

Deshmukh AJ, Pant S, Cook J, Sachdeva R, Rutlen D, Uretsky BF.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1123-5. doi: 10.1345/aph.1R062. Epub 2012 Jul 17. No abstract available.

PMID:
22811344
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk